Virios Therapeutics prices $1.7M public offering of 8.5M shares at $0.20/share for Long-COVID study prep

Dogwood Therapeutics, Inc.

Priced public offering of 8,500,000 shares at $0.20 per share for gross proceeds of approx. $1.7M.
Net proceeds to fund preparatory activities for planned IMC-2 Long-COVID Phase 2b study and general corporate purposes.
Offering expected to close on May 22, 2024; Maxim Group LLC acting as sole placement agent.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.